NobleBlocks

Research indexObservational

Reply

Liao, Taghinia, May and 1 other

Plastic & Reconstructive Surgery14 Oct 2008

NobleIDark:/48914/w1/20260524/3120D8B5DOI10.1097/prs.0b013e318186cc30

Paywalled

The full text is at the publisher

You can read the abstract here, or open it at the publisher.

Read at the publisher

Abstract

Sir: We appreciate the comments by Dr. Knobloch and colleagues on our article entitled “Incidence of Hematoma Complication with Heparin Venous Thrombosis Prophylaxis after TRAM Flap Breast Reconstruction,” raising the question of heparin-induced thrombocytopenia. It has been well established by numerous studies across surgical and medical disciplines that venous thrombosis chemoprophylaxis with heparin is effective, and it has been well reviewed in practice guidelines.1,2 Nevertheless, plastic surgeons are often concerned with the use of heparin in patients after procedures that involve extensive soft-tissue undermining. The goal of our study was to determine whether the use of heparin actually increased the rate of hematoma requiring operative intervention, studying patients after transverse rectus abdominis musculocutaneous flap breast reconstruction as a model population. Our data showed that the hematoma rate did not increase with heparin chemoprophylaxis, suggesting that heparin use is worthwhile, because venous thrombosis is common and pulmonary embolus often fatal. Heparin-induced thrombocytopenia is an increasingly recognized clinical entity, most often in cardiac surgery patients. Knobloch and colleagues succinctly summarized the cause of heparin-induced thrombocytopenia. We did recognize the importance of heparin-induced thrombocytopenia and examined its incidence in our patient population. We studied 392 patients who received subcutaneous heparin: 375 patients received unfractionated and 17 received low-molecular-weight heparin. There were 61 patients who received an intravenous heparin bolus in the context of free transverse rectus abdominis musculocutaneous flap reconstruction. As we noted at the end of the Results section, we specifically looked for but detected no cases of heparin-induced thrombocytopenia. Therefore, our study provides the first large case series in plastic surgery demonstrating that the incidence of heparin-induced thrombocytopenia is quite low, less than 0.26 percent. Several studies on the incidence of heparin-induced thrombocytopenia offer guidance in preoperative risk stratification. Smythe and colleagues conducted a retrospective study of over 24,000 patients and found the overall incidence of heparin-induced thrombocytopenia to be 0.2 percent.3 The incidence of heparin-induced thrombocytopenia is 3.8 times greater in patients exposed to intravenous versus subcutaneous heparin administration. Moreover, over 50 percent of heparin-induced thrombocytopenia cases were in cardiac surgery patients. It has been shown that the incidence of heparin-induced thrombocytopenia is lower in patients treated with low-molecular-weight heparin, as compared with unfractionated heparin.4 Therefore, although heparin-induced thrombocytopenia can have devastating consequences, it is a clinical entity we rarely encounter in plastic surgery. Balanced against the relatively common occurrence of venous thrombosis, we maintain that chemoprophylaxis with heparinoids should be considered in patients at risk, mindful of heparin-induced thrombocytopenia as a rare complication. In the average patient without prior heparin exposure, heparin-induced thrombocytopenia concern should not dissuade one from venous thrombosis chemoprophylaxis. Eric C. Liao, M.D., Ph.D. Division of Plastic Surgery Brigham and Women’s Hospital Harvard Medical School Amir H. Taghinia, M.D. Harvard Medical School James W. May, Jr., M.D. Division of Plastic Surgery Massachusetts General Hospital Harvard Medical School Dennis P. Orgill, M.D., Ph.D. Division of Plastic Surgery Brigham and Women’s Hospital Harvard Medical School Boston, Mass.

Discussion

Citations

Topics

More

Suggest a correction or report